Evidence map›Paper›PMID 38794330›Full record

ArticlePharmaceutics2024

Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment.

Natalia Ponomareva, Sergey Brezgin, Ivan Karandashov, Anastasiya Kostyusheva, Polina Demina, Olga Slatinskaya, Ekaterina Bayurova, Denis Silachev, Vadim S Pokrovsky, Vladimir Gegechkori and 8 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Natalia PonomarevaLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
Sergey BrezginLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0003-4792-0739
Ivan KarandashovLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0001-6517-6136
Anastasiya KostyushevaLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
Polina DeminaInstitute of Physics, Technology, and Informational Systems, Moscow Pedagogical State University, Malaya Pirogovskaya St. 1, 119435 Moscow, Russia.ORCID 0000-0001-6349-2979
Olga SlatinskayaFaculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-9908-2637
Ekaterina BayurovaChumakov Federal Scientific Center for Research and Development of Immunobiological Products, Russian Academy of Sciences (Polio Institute), 108819 Moscow, Russia.ORCID 0000-0002-6160-2203
Denis SilachevV.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 117997 Moscow, Russia.ORCID 0000-0003-0581-9755
Vadim S PokrovskyDivision of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia.
Vladimir GegechkoriDepartment of Pharmaceutical and Toxicological Chemistry, Sechenov First Moscow State Medical University, 119146 Moscow, Russia.
Evgeny KhaydukovInstitute of Physics, Technology, and Informational Systems, Moscow Pedagogical State University, Malaya Pirogovskaya St. 1, 119435 Moscow, Russia.ORCID 0000-0002-3900-2949
Georgy MaksimovFaculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-7377-0773
Anastasia FrolovaDivision of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia.ORCID 0000-0002-6980-0028
Ilya GordeychukChumakov Federal Scientific Center for Research and Development of Immunobiological Products, Russian Academy of Sciences (Polio Institute), 108819 Moscow, Russia.ORCID 0000-0002-4551-7535
Andrey A ZamyatninDivision of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia.ORCID 0000-0002-3046-4565
Vladimir ChulanovLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0001-6303-9293
Alessandro ParodiDivision of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia.ORCID 0000-0003-0985-6545
Dmitry KostyushevLaboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0002-1851-7441

Funding

Ministry of Science and Higher Education of Russia 075-01551-23-00Russian Science Foundation 21-75-30020
6 · The paper itself

Abstract

Biological nanoparticles (NPs), such as extracellular vesicles (EVs), exosome-mimetic nanovesicles (EMNVs) and nanoghosts (NGs), are perspective non-viral delivery vehicles for all types of therapeutic cargo. Biological NPs are renowned for their exceptional biocompatibility and safety, alongside their ease of functionalization, but a significant challenge arises when attempting to load therapeutic payloads, such as nucleic acids (NAs). One effective strategy involves fusing biological NPs with liposomes loaded with NAs, resulting in hybrid carriers that offer the benefits of both biological NPs and the capacity for high cargo loads. Despite their unique parameters, one of the major issues of virtually any nanoformulation is the ability to escape degradation in the compartment of endosomes and lysosomes which determines the overall efficiency of nanotherapeutics. In this study, we fabricated all major types of biological and hybrid NPs and studied their response to the acidic environment observed in the endolysosomal compartment. In this study, we show that EMNVs display increased protonation and swelling relative to EVs and NGs in an acidic environment. Furthermore, the hybrid NPs exhibit an even greater response compared to EMNVs. Short-term incubation of EMNVs in acidic pH corresponding to late endosomes and lysosomes again induces protonation and swelling, whereas hybrid NPs are ruptured, resulting in the decline in their quantities. Our findings demonstrate that in an acidic environment, there is enhanced rupture and release of vesicular cargo observed in hybrid EMNVs that are fused with liposomes compared to EMNVs alone. This was confirmed through PAGE electrophoresis analysis of mCherry protein loaded into nanoparticles. In vitro analysis of NPs colocalization with lysosomes in HepG2 cells demonstrated that EMNVs mostly avoid the endolysosomal compartment, whereas hybrid NPs escape it over time. To conclude, (1) hybrid biological NPs fused with liposomes appear more efficient in the endolysosomal escape via the mechanism of proton sponge-associated scavenging of protons by NPs, influx of counterions and water, and rupture of endo/lysosomes, but (2) EMNVs are much more efficient than hybrid NPs in actually avoiding the endolysosomal compartment in human cells. These results reveal biochemical differences across four major types of biological and hybrid NPs and indicate that EMNVs are more efficient in escaping or avoiding the endolysosomal compartment.

Indexed as

biological barrierscancerCRISPR/Casdynamic light scatteringexosomesgene editingnanoparticle-tracking assayproton spongeRNAsmall moleculessurface-enhanced Raman spectroscopyvaccines

Identifiers

PMID38794330
PMCPMC11126099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.